Potential Drug Targets in Mycobacterial Cell Wall: Non-Lipid Perspective.


Journal

Current drug discovery technologies
ISSN: 1875-6220
Titre abrégé: Curr Drug Discov Technol
Pays: United Arab Emirates
ID NLM: 101157212

Informations de publication

Date de publication:
2020
Historique:
received: 10 03 2018
revised: 21 05 2018
accepted: 22 05 2018
pubmed: 8 6 2018
medline: 6 7 2021
entrez: 8 6 2018
Statut: ppublish

Résumé

Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB), still remains a deadly disease worldwide. With prolonged usage of anti-TB drugs, the current therapeutic regimes are becoming ineffective, particularly due to emergence of drug resistance in MTB. Under such compelling circumstances, it is pertinent to look for new drug targets. The cell wall envelope of MTB is composed of unique lipids that are frequently targeted for anti-TB therapy. This is evident from the fact that most of the commonly used front line drugs (Isoniazid and Ethambutol) act on lipid machinery of MTB. Thus, despite the fact that much of the attention is towards understanding the MTB lipid biology, in search for identification of new drug targets, our knowledge of bacterial cell wall non-lipid components remains rudimentary and underappreciated. Better understanding of such components of mycobacterial cell structure will help in the identification of new drug targets that can be utilized on the persistent mycobacterium. This review at a common platform summarizes some of the non-lipid cell wall components in MTB that have potential to be exploited as future drug targets.

Identifiants

pubmed: 29875004
pii: CDDT-EPUB-90936
doi: 10.2174/1570163815666180605113609
doi:

Substances chimiques

Antitubercular Agents 0
Bacterial Proteins 0
Hemagglutinins 0
Membrane Lipids 0
Polysaccharides, Bacterial 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

147-153

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Shrayanee Das (S)

Amity Institute of Biotechnology, Amity University Haryana, Gurugram (Manesar)-122413, India.

Saif Hameed (S)

Amity Institute of Biotechnology, Amity University Haryana, Gurugram (Manesar)-122413, India.

Zeeshan Fatima (Z)

Amity Institute of Biotechnology, Amity University Haryana, Gurugram (Manesar)-122413, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH